BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 10097744)

  • 1. [Clinical evaluation of S-1, a new anticancer agent, in patients with advanced gastrointestinal cancer. S-1 Cooperative Gastrointestinal Study Group].
    Maehara Y; Sugimachi K; Kurihara M; Taguchi T
    Gan To Kagaku Ryoho; 1999 Mar; 26(4):476-85. PubMed ID: 10097744
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Early phase II study of S-1 in patients with advanced head and neck cancer. S-1 Cooperative Study Group (Head and Neck Working Group)].
    Inuyama Y; Kida A; Tsukuda M; Kohno N; Satake B
    Gan To Kagaku Ryoho; 1998 Jul; 25(8):1151-8. PubMed ID: 9679577
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [New oral anticancer drug, TS-1 (S-1)--from bench to clinic].
    Shirasaka T; Tsukuda M; Inuyama Y; Taguchi T
    Gan To Kagaku Ryoho; 2001 Jun; 28(6):855-64. PubMed ID: 11432358
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Conceptual changes in cancer chemotherapy--biochemical modulation of 5-FU].
    Shirasaka T; Yamamitsu S; Tsuji A; Terashima M; Hirata K
    Gan To Kagaku Ryoho; 2000 Jun; 27(6):832-45. PubMed ID: 10897209
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I and pharmacokinetic study of the oral fluoropyrimidine S-1 on a once-daily-for-28-day schedule in patients with advanced malignancies.
    Chu QS; Hammond LA; Schwartz G; Ochoa L; Rha SY; Denis L; Molpus K; Roedig B; Letrent SP; Damle B; DeCillis AP; Rowinsky EK
    Clin Cancer Res; 2004 Aug; 10(15):4913-21. PubMed ID: 15297391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Timeline from discovery of 5-FU to development of an oral anticancer agent S-1 and its drug concept].
    Shirasaka T; Taguchi T
    Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():4-18. PubMed ID: 16897967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Combination therapy of continuous venous infusion (CVI) of 5-FU and low dose consecutive cisplatin (CDDP), and the new oral anti-cancer drug S-1 for advanced gastro-intestinal cancer].
    Shirasaka T; Aiba K; Araki H; Suzuki M; Terashima M; Mikami Y
    Gan To Kagaku Ryoho; 1999 Mar; 26(4):456-66. PubMed ID: 10097742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I and pharmacokinetic study of once daily oral administration of S-1 in patients with advanced cancer.
    Cohen SJ; Leichman CG; Yeslow G; Beard M; Proefrock A; Roedig B; Damle B; Letrent SP; DeCillis AP; Meropol NJ
    Clin Cancer Res; 2002 Jul; 8(7):2116-22. PubMed ID: 12114411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug.
    Hirata K; Horikoshi N; Aiba K; Okazaki M; Denno R; Sasaki K; Nakano Y; Ishizuka H; Yamada Y; Uno S; Taguchi T; Shirasaka T
    Clin Cancer Res; 1999 Aug; 5(8):2000-5. PubMed ID: 10473078
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rapid development of S-1 in the west for therapy of advanced gastric carcinoma.
    Ajani JA
    Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():117-20. PubMed ID: 16897985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Invention of a tumor-selective 5-fluorouracil derivative named S-1 by biochemical modulation of 5-fluorouracil].
    Shirasaka T; Shimamoto Y; Kato T; Fukushima M
    Gan To Kagaku Ryoho; 1998 Feb; 25(3):371-84. PubMed ID: 9492831
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of food on the pharmacokinetics of S-1 after single oral administration to patients with solid tumors.
    Peters GJ; Noordhuis P; Van Groeningen CJ; Giaccone G; Holwerda U; Voorn D; Schrijvers A; Schornagel JH; Beijnen JH; Fumoleau P; Schellens JH
    Clin Cancer Res; 2004 Jun; 10(12 Pt 1):4072-6. PubMed ID: 15217941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [An early phase II clinical study of S-1 in patients with breast cancer. S-1 Cooperative Study Group (Breast Cancer Working Group)].
    Taguchi T; Morimoto K; Horikoshi N; Takashima S; Toge T; Kimura M; Sano M; Aoyama H; Ota J; Noguchi S
    Gan To Kagaku Ryoho; 1998 Jun; 25(7):1035-43. PubMed ID: 9644319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pharmacokinetics of S-1].
    Hirata K; Horikoshi N; Tominaga K; Sohma K; Yamaguchi K; Okazaki M; Furuhata T; Sasaki K; Nakano Y; Ishizuka H; Yamada Y; Uno S; Taguchi T; Yamamitsu S; Shirasaka T
    Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():27-35. PubMed ID: 16897969
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A pilot study of low-dose TS-1 and cisplatin combination chemotherapy for advanced gastric cancer].
    Kamata T; Hayashi Y; Minatoya G; Michiwa Y; Onishi I; Takeda T; Koyasaki N; Kanno M
    Gan To Kagaku Ryoho; 2001 Oct; 28(10):1419-22. PubMed ID: 11681250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Antitumor activity and function of S-1, a new oral tegafur-based formulation].
    Fukushima M
    Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():19-26. PubMed ID: 16897968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Two elderly patients with advanced gastric cancer responding to chronomodulation chemotherapy with tegafur + cisplatin + isovorin followed by oral administration of S-1].
    Kobayashi A; Yamaguchi M
    Gan To Kagaku Ryoho; 2001 Jul; 28(7):1003-7. PubMed ID: 11478129
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [A late phase II clinical study of S-1 in patients with progressed, refractory breast cancer].
    Saeki T; Takashima S; Sano M; Horikoshi N; Miura S; Shimizu S; Morimoto K; Kimura M; Taguchi T
    Gan To Kagaku Ryoho; 2004 Apr; 31(4):539-47. PubMed ID: 15114697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Concentration of FT and CDHP and 5-FU in the ascites fluid of patient with peritoneal carcinomatosis after new anti-cancer drug TS-1 oral administration].
    Iizuka R; Takahashi S; Kakihara N; Matsumura H; Takenaka A
    Gan To Kagaku Ryoho; 2002 Jul; 29(7):1251-3. PubMed ID: 12146009
    [No Abstract]   [Full Text] [Related]  

  • 20. Pharmacokinetics of S-1, an oral formulation of ftorafur, oxonic acid and 5-chloro-2,4-dihydroxypyridine (molar ratio 1:0.4:1) in patients with solid tumors.
    Peters GJ; Noordhuis P; Van Kuilenburg AB; Schornagel JH; Gall H; Turner SL; Swart MS; Voorn D; Van Gennip AH; Wanders J; Holwerda U; Smid K; Giaccone G; Fumoleau P; Van Groeningen CJ
    Cancer Chemother Pharmacol; 2003 Jul; 52(1):1-12. PubMed ID: 12739060
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.